The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT04572724

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04572724
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04572724. Non-randomized; no masking; primary purpose treatment. Start 2020-07-06 (actual); primary completion 2022-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value
Condition
Peritoneal Dialysis Complication
Condition
Hemodialysis Complication
Condition
Heart Failure
Intervention (Drug)
Sacubitril / Valsartan Oral Tablet
Intervention (Drug)
RAS Inhibitors
Lead sponsor
Shenzhen Second People's Hospital (class: other)

Record details

Record id
cardio:ct-nct04572724
Content hash
fd96848f88cee677f99daeeab8585a9968b249c3eabafd214830eea91ba390cd